scholarly journals Genetic variants in glutamine metabolic pathway genes predict cutaneous melanoma‐specific survival

2019 ◽  
Vol 58 (11) ◽  
pp. 2091-2103 ◽  
Author(s):  
Ka Chen ◽  
Hongliang Liu ◽  
Zhensheng Liu ◽  
Wendy Bloomer ◽  
Christopher I. Amos ◽  
...  
Keyword(s):  
Metabolic Pathway ◽  
Cutaneous Melanoma ◽  
Genetic Variants

scholarly journals Genetic variants in the folate metabolic pathway genes predict cutaneous melanoma‐specific survival

2020 ◽  
Vol 183 (4) ◽  
pp. 719-728
Author(s):  
W. Dai ◽  
H. Liu ◽  
Y. Liu ◽  
X. Xu ◽  
D. Qian ◽  
...  
Keyword(s):  
Metabolic Pathway ◽  
Cutaneous Melanoma ◽  
Genetic Variants

scholarly journals Genetic variants in PDSS1 and SLC16A6 of the ketone body metabolic pathway predict cutaneous melanoma-specific survival

2020 ◽  
Vol 59 (6) ◽  
pp. 640-650
Author(s):  
Wei Dai ◽  
Hongliang Liu ◽  
Ka Chen ◽  
Xinyuan Xu ◽  
Danwen Qian ◽  
...  
Keyword(s):  
Metabolic Pathway ◽  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Ketone Body

scholarly journals Genetic variants of SDCCAG8 and MAGI2 in mitosis‐related pathway genes are independent predictors of cutaneous melanoma‐specific survival

2021 ◽  
Author(s):  
Yuanmin He ◽  
Hongliang Liu ◽  
Sheng Luo ◽  
Christopher I. Amos ◽  
Jeffrey E. Lee ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Related Pathway

scholarly journals Genetic variants in RUNX3 , AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients

2019 ◽  
Vol 145 (3) ◽  
pp. 621-631 ◽  
Author(s):  
Ka Chen ◽  
Hongliang Liu ◽  
Zhensheng Liu ◽  
Sheng Luo ◽  
Edward F. Patz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Metabolic Pathway ◽  
Genetic Variants ◽  
Nonsmall Cell Lung Cancer ◽  
Lung Cancer Patients

scholarly journals Genetic variants in the vitamin D pathway genesVDBP andRXRAmodulate cutaneous melanoma disease-specific survival

2016 ◽  
Vol 29 (2) ◽  
pp. 176-185 ◽  
Author(s):  
Jieyun Yin ◽  
Hongliang Liu ◽  
Xiaohua Yi ◽  
Wenting Wu ◽  
Christopher I. Amos ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Disease Specific Survival ◽  
Disease Specific

scholarly journals Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival

2016 ◽  
Vol 140 (6) ◽  
pp. 1270-1279 ◽  
Author(s):  
Hongyu Li ◽  
Yanru Wang ◽  
Hongliang Liu ◽  
Qiong Shi ◽  
Yinghui Xu ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Integrin Signaling

scholarly journals Genetic Variants of the Vitamin D Receptor Gene Alter Risk of Cutaneous Melanoma

2007 ◽  
Vol 127 (2) ◽  
pp. 276-280 ◽  
Author(s):  
Chunying Li ◽  
Zhensheng Liu ◽  
Zhengdong Zhang ◽  
Sara S. Strom ◽  
Jeffrey E. Gershenwald ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene

Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e14556-e14556
Author(s):  
J. Li ◽  
X. Sha ◽  
P. LoRusso
Keyword(s):  
Metabolic Pathway ◽  
Genetic Variants ◽  
Parp Inhibitor ◽  
Liver Microsomes ◽  
Therapeutic Outcome ◽  
Cytotoxic Agents ◽  
Wild Type ◽  
Metabolite Formation ◽  
Drug Concentrations

e14556 Background: Poly(ADP-ribose) polymerase (PARP) is essential for single-stranded DNA break repair and repair of DNA damage can lead to radio- and chemo-resistance. Thus, inhibition of PARP activity can sensitize cells to cytotoxic therapies. ABT-888 is a potent, orally bioavailable PARP inhibitor. Preclinical studies suggest that ABT-888 potentiates multiple cytotoxic agents and its efficacy is correlated with plasma/tumor drug concentrations. The objective of this study was to determine the pharmacogenetic effect of genetic variants in the ABT-888 metabolic pathway, with the aim to better understand molecular basis of the variation in ABT-888 pharmacokinetics (PK) and therapeutic outcome. Methods: The major enzymes responsible for ABT-888 metabolism were identified by in vitro metabolism studies with specific recombinant human cytochrome P450 (CYP) enzymes. The functional significance of genetic variants of the identified enzymes was assessed by examining ABT-888 metabolic kinetics by candidate variant enzymes and microsomes. The association of the functional significant genetic variants with the PK and clinical outcome is being evaluated in the context of an ongoing phase I trial in which ABT-888 is administered in combination with irinotecan in patients with advanced solid tumors. Results: ABT-888 was metabolized predominantly by human CYP2D6, to a less extent by CYP1A1, and to a negligible extent by CYP1A2, 2C9, 2C19, 3A4, and 3A5. CYP2D6*10 exhibited markedly reduced catalytic capability in ABT-888 overall metabolism and the metabolite (A-925088) formation, with in vitro maximum clearance being 31% and 5.3%, respectively, of that estimated from the wild-type CYP2D6. In human liver microsomes carrying homozygous CYP2D6*4, the rates of parent drug disappearance and metabolite formation were significantly lower than those observed in the microsomes carrying wild-type CYP2D6, P < 0.05. Conclusions: CYP2D6 is the predominant enzyme responsible for the hepatic metabolism of ABT-888. Common allelic variants CYP2D6*10 and *4 are associated with significantly reduced metabolic activity towards ABT-888. CYP2D6 polymorphisms may influence the PK and therapeutic outcome of ABT-888. Its clinical relevance remains to be determined. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document